Randomised clinical trial of medical evacuation and surgical curettage for incomplete miscarriageBMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7006.662 (Published 09 September 1995) Cite this as: BMJ 1995;311:662
- E T M de Jonge, senior consultanta,
- J D Makin, clinical epidemiologista,
- E Manefeldt, registrara,
- G H De Wet, senior consultanta,
- R C Pattinson, professora
- a Department of Obstetrics and Gynaecology, Kalafong Hospital, University of Pretoria, Private Bag X 396, Pretoria 0001, Republic of South Africa
- Correspondence to: Dr de Jonge.
- Accepted 29 June 1995
In South Africa surgical curettage under general anaesthesia is considered to be the standard management for incomplete miscarriage. It constitutes a substantial proportion of the gynaecological services rendered and therefore places an ever increasing burden on the medical resources available. Research into the safety and efficacy of outpatient surgical curettage has resulted in a cost effective procedure with minimal illness.1 2 Henshaw et al, however, have shown that medical management of an uncomplicated incomplete first trimester miscarriage with misoprostol, a synthetic prostaglandin analogue, had a 96% success rate and may be a suitable cost saving alternative.3 We compared medical with surgical management in terms of efficacy and morbidity.
Patients, methods, and results
We conducted a randomised clinical trial of 50 consecutive patients fulfilling the following eligibility criteria: history of amenorrhoea followed by abdominal cramping and vaginal bleeding; uterine size </=14 weeks of gestation, evaluated clinically before randomisation; dilated cervical os and palpable products of conception; no foul smelling products; temperature <37.5°C; no excessive vaginal bleeding requiring immediate surgical evacuation; haemoglobin concentration >90 g/l after resuscitation; and no contraindication to prostaglandin treatment.
Medical management consisted of a single dose of misoprostol 400 μg orally and was considered to be successful if bleeding had reverted to a blood stained discharge, pain had subsided, the uterus was smaller, and the cervical opening had closed on repeat pelvic examination 12 hours after misoprostol administration. Pelvic ultrasonography was performed when uncertainty existed about the completeness of the abortion. Surgical curettages were performed twice a day. A hundred opaque sealed envelopes were randomised by means of computer generated random numbers.
Even numbers were assigned to misoprostol and odd numbers to surgical evacuation. The study was approved by the hospital ethics committee. Informed consent was obtained in all cases. No case was excluded because of excessive bleeding. The protocol included an interim analysis of 50 cases, and after analysis the study was stopped. This resulted in differences in size of the two groups. The χ2, Mann-Whitney U, and Wilcoxon matched pairs tests were used for statistical analysis where appropriate.
The table summarises demographic data and findings. The two groups were comparable in terms of the entry criteria. Only 3 (13%) of the women receiving misoprostol had a successful evacuation compared with 26 (97%) of the women in the surgical group (P<0.00001). In the misoprostol group there was a significant fall in haemoglobin concentration after treatment (P=0.04), whereas no difference was found in the surgical group (P=0.76).
Although expectant management of the first trimester miscarriage is increasingly advocated in countries with good access to medical services,4 5 cost effective high turnover management strategies are more realistic for developing countries.2 The concept of medical management in fact addresses these needs. Our results, however, could not confirm the efficacy of a single dose of misoprostol 400 μg in completing the expulsion of the retained products of conception. The mean duration of amenorrhoea in this study was 80 days compared with the 66 days in the study of Henshaw et al.3 Although the decision to proceed with a surgical curettage was made 12 hours after misoprostol administration, all 20 patients in whom misoprostol failed were observed for an extended period (median 17 hours, range 13-23) while awaiting curettage; none had a successful outcome during this time. Most of the patients in the misoprostol group continued to bleed, and this was reflected in a significant fall in haemoglobin concentration (P=0.04; table).
As no drug related complications were encountered in the misoprostol group, further randomised trials using higher dosages of misoprostol or in combination with mifepristone when available are necessary to determine the place of medical management of incomplete miscarriage.
Funding Reproductive Health Research Fund.
Conflict of interest None.